
Imunon Inc (IMNN) Stock Forecast & Price Target
Imunon Inc (IMNN) Analyst Ratings
Bulls say
Imunon Inc. has demonstrated promising clinical results from its Phase II trial of IMNN-001, with many patients exhibiting sustained positive outcomes that have resulted in improved hazard ratios and overall survival metrics. The ongoing development of IMNN-001, which has shown a significant median overall survival advantage and a favorable safety profile, positions the company favorably as it prepares to initiate a pivotal Phase 3 trial, with recent FDA meetings indicating strong alignment on trial design. The continued strengthening of the clinical data supports the potential of Imunon's DNA-mediated immunotherapy platform, enhancing confidence in its prospects for successful market entry and patient impact.
Bears say
Imunon Inc's stock faces a negative outlook due to concerns regarding delayed regulatory approvals for its therapies, with potential European approval staggered by three years behind the anticipated U.S. timeline, suggesting a slower market entry and revenue generation. Despite a year-over-year decline of 9% in operating expenses attributed to effective cost management, the company's financial health may still be challenged by the lengthy path to commercialization of its lead product, IMNN-001, in treating ovarian cancer. Furthermore, uncertainties surrounding the clinical outcomes and market acceptance of its COVID-19 booster vaccine, IMNN-101, also contribute to potential risks impacting future financial performance and investor confidence.
This aggregate rating is based on analysts' research of Imunon Inc and is not a guaranteed prediction by Public.com or investment advice.
Imunon Inc (IMNN) Analyst Forecast & Price Prediction
Start investing in Imunon Inc (IMNN)
Order type
Buy in
Order amount
Est. shares
0 shares